Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma stocks lead the losses
Tue, 29 Sep 11:30 am

After opening the day on a bearish note, the Indian Indices continued to trade negatively. Sectoral indices are trading on a discouraging note with mining and pharma stocks bearing maximum burnt.The BSE-Sensex is trading down 23 points (down 0.1%) and the NSE-Nifty is trading down 15 points (down 0.2%). The BSE Mid Cap index and the BSE Small Cap index are also trading negatively, down by 0.3% and 0.4% respectively. The rupee is trading at 66.23 to the US$.

Most of the pharma stocks are trading negatively with Glenmark Pharma and Dr Reddy's Laboratories leading the losses. As per an article in Business Standard, Dr Reddy's Laboratories is said to be buying intellectual property rights of Fondaparinux, the anti-coagulant drug, from Australian company Alchemia. The buyout is for US$ 17.5 m in cash on closing of the transaction basis. The product is said to be a good revenue contributor for Dr Reddy's which now will not have to share profits with Alchemia. Furthermore, on a separate note, the company has also settled litigation to sell generic Kuvan, a US$ 107 m drug. Scrip of Dr Reddy's Laboratories is presently trading down by 3.2%.

Stocks in the engineering space are trading mixed with BEML Ltd and Crompton Greaves witnessing maximum selling pressure. As per a leading financial daily, Crompton Greaves has bagged an order from Spanish utility Gas Natural Fenosa (GNF) for supplying ZIV single and three phased smart meters. The order is finalized for a worth of Rs 1.25 bn. Further, ZIV smart meters of the company will cover large part of the demand for domestic meters from GNF, having won the order of supplying 7,50,000 singly phase smart meters last year. GNF is a leading multinational group in energy sector and a pioneer in integration of gas and electricity. Stock of Crompton Greaves is trading down by 2.7% on the BSE.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma stocks lead the losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.